# Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

> **NCT02678299** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University of Aarhus** · enrollment: 60 (actual)

## Conditions studied

- Malignant Lymphoma

## Interventions

- **DRUG:** PREBEN

## Key facts

- **NCT ID:** NCT02678299
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-02
- **Primary completion:** 2022-02
- **Final completion:** 2025-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02678299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02678299, "Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02678299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*